U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H33Cl2NO5
Molecular Weight 486.429
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VILANTEROL

SMILES

OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl

InChI

InChIKey=DAFYYTQWSAWIGS-DEOSSOPVSA-N
InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1

HIDE SMILES / InChI
Molecular Formula C24H33Cl2NO5
Molecular Weight 486.429
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:40:33 UTC 2023
Edited
by admin
on Fri Dec 15 17:40:33 UTC 2023
Record UNII
028LZY775B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VILANTEROL
INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
VILANTEROL [USAN]
Common Name English
1,3-BENZENEDIMETHANOL, .ALPHA.1-(((6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYL)AMINO)METHYL)-4-HYDROXY-, (.ALPHA.1R)-
Common Name English
VILANTEROL [VANDF]
Common Name English
GW642444
Code English
vilanterol [INN]
Common Name English
GW-642444
Code English
Vilanterol [WHO-DD]
Common Name English
GW642444X
Code English
GW-642444X
Code English
4-{(1R)-2-[(6-{2-[(2,6-Dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
Systematic Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS LAVENTAIR (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
WHO-ATC R03AL08
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
NDF-RT N0000175779
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
WHO-VATC QR03AL03
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
NCI_THESAURUS C48149
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
WHO-ATC R03AL03
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
EMA ASSESSMENT REPORTS RELVAR ELLIPTA (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
NCI_THESAURUS C319
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
WHO-ATC R03AK10
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
WHO-VATC QR03AK10
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
Code System Code Type Description
IUPHAR
7353
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
RXCUI
1424884
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY RxNorm
SMS_ID
100000138094
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
LACTMED
Vilanterol
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
CAS
503068-34-6
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
USAN
UU-68
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
DAILYMED
028LZY775B
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
EPA CompTox
DTXSID80198318
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
DRUG BANK
DB09082
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
ChEMBL
CHEMBL1198857
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
INN
9198
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
PUBCHEM
10184665
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
MESH
C550468
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
NCI_THESAURUS
C152875
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
DRUG CENTRAL
4799
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
CHEBI
75037
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
WIKIPEDIA
Vilanterol
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
FDA UNII
028LZY775B
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
EVMPD
SUB77409
Created by admin on Fri Dec 15 17:40:33 UTC 2023 , Edited by admin on Fri Dec 15 17:40:33 UTC 2023
PRIMARY
Related Record Type Details
Structure of VILANTEROL TRIFENATATE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BETA-2 ADRENERGIC RECEPTOR
TARGET -> AGONIST
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
However, because of low oral bioavailability, inhibition of P-gp is unlikely to have an impact on the overall bioavailability of vilanterol.
Related Record Type Details
Structure of 5-((1R)-2-((6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYL)AMINO)-1-HYDROXYETHYL)-2-HYDROXYBENZOIC ACID
METABOLITE -> PARENT
PLASMA
Structure of GLYCINE, N-(6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYL)-
METABOLITE -> PARENT
URINE
Structure of 6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYLAMINE
METABOLITE -> PARENT
PLASMA
Structure of (2S,3S,4S,5R,6S)-6-(4-((1R)-2-(6-(CARBOXYMETHYLOXY)HEXYLAMINO)-1-HYDROXY-ETHYL)-2-(HYDROXYMETHYL)PHENOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of GLYCINE, N-(6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYL)-
METABOLITE -> PARENT
PLASMA
Structure of 6-(((2R)-2-HYDROXY-2-(4-HYDROXY-3-(HYDROXYMETHYL)PHENYL)ETHYL)AMINO)HEXANOIC ACID
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of 6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYLAMINE
METABOLITE INACTIVE -> PARENT
human beta-2 cAMP LANCE assay (n=7-24), a value is mean pEC50 (-logEC50); Vilanterol's beta-2 activity is 10.4 (pEC50)
IN-VITRO
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 4-((1R)-2-((5-CARBOXYPENTYL)AMINO)-1-HYDROXYETHYL)-2-(HYDROXYMETHYL)PHENYL
METABOLITE -> PARENT
URINE
Structure of GW-630200
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of GSK-932009
METABOLITE -> PARENT
FECAL
Structure of 2-HYDROXY-5-((1R)-1-HYDROXY-2-((6-HYDROXY-6-OXO-HEXYL)AMINO)ETHYL)BENZOIC ACID
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 4-((1R)-2-((5-CARBOXYPENTYL)AMINO)-1-HYDROXYETHYL)-2-(HYDROXYMETHYL)PHENYL
METABOLITE -> PARENT
PLASMA
Structure of GSK-932009
METABOLITE -> PARENT
URINE
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 4-((1R)-1-HYDROXY-2-((6-(2-HYDROXYETHOXY)HEXYL)AMINO)ETHYL)-2-(HYDROXYMETHYL)PHENYL
METABOLITE -> PARENT
URINE
Structure of 6-(2-((2,6-DICHLOROPHENYL)METHOXY)ETHOXY)HEXYLAMINE
METABOLITE -> PARENT
URINE
Structure of GSK-932009
METABOLITE INACTIVE -> PARENT
human beta-1 cAMP LANCE assay (n=7-24), a value is mean pEC50 (-logEC50); Vilanterol's beta-1 activity is 7.0 (pEC50)
IN-VITRO
Related Record Type Details
Structure of VILANTEROL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

blood-to-plasma ratio PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966